Details for Patent: 9,891,239
✉ Email this page to a colleague
Which drugs does patent 9,891,239 protect, and when does it expire?
Patent 9,891,239 protects GENVOYA and STRIBILD and is included in two NDAs.
Protection for GENVOYA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has one hundred and ninety-seven patent family members in thirty-three countries.
Summary for Patent: 9,891,239
| Title: | Modulators of pharmacokinetic properties of therapeutics |
| Abstract: | The present application provides for a compound of Formula IV, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent. |
| Inventor(s): | Desai; Manoj C. (Pleasant Hill, CA), Liu; Hongtao (Cupertino, CA), Xu; Lianhong (Palo Alto, CA) |
| Assignee: | Gilead Sciences, Inc. (Foster City, CA) |
| Application Number: | 12/528,185 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,891,239 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; |
Drugs Protected by US Patent 9,891,239
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | GENVOYA | cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 207561-001 | Nov 5, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Gilead Sciences Inc | STRIBILD | cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate | TABLET;ORAL | 203100-001 | Aug 27, 2012 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,891,239
| PCT Information | |||
| PCT Filed | February 22, 2008 | PCT Application Number: | PCT/US2008/054788 |
| PCT Publication Date: | August 28, 2008 | PCT Publication Number: | WO2008/103949 |
International Family Members for US Patent 9,891,239
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2049506 | ⤷ Sign Up | CA 2015 00060 | Denmark | ⤷ Sign Up |
| European Patent Office | 2049506 | ⤷ Sign Up | PA2015040 | Lithuania | ⤷ Sign Up |
| European Patent Office | 2049506 | ⤷ Sign Up | 92864 | Luxembourg | ⤷ Sign Up |
| European Patent Office | 2049506 | ⤷ Sign Up | 15C0078 | France | ⤷ Sign Up |
| European Patent Office | 2049506 | ⤷ Sign Up | 300780 | Netherlands | ⤷ Sign Up |
| European Patent Office | 2049506 | ⤷ Sign Up | 61/2015 | Austria | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
